Brief: Agomab Announces First Patient Dosed In Global Nov-Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease
13/10/2026 21:14
BRIEF-Agomab Announces First Patient Dosed In Global Nov-Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease Agomab Therapeutics NV AGMB.O:
AGOMAB ANNOUNCES FIRST PATIENT DOSED IN GLOBAL NOV-ERA PHASE 2B STUDY OF ONTUNISERTIB IN FIBROSTENOSING CROHN'S DISEASE
AGOMAB THERAPEUTICS NV - NOV-ERA PHASE 2B STUDY EXPECTED TO ENROLL ABOUT 320 PATIENTS GLOBALLY
Source text: ID:nGNX31Vcl9
Further company coverage: AGMB.O
Recent news on Agomab Therapeutics NV
See all newsBrief: Agomab Announces First Patient Dosed In Global Nov-Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Brief: Agomab Reports Positive Topline Data From Stenova Open-Label Extension Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Brief: Agomab Announces Appointments Of Marino Garcia And Dr Naimish Patel To Board Of Directors
Brief: Agomab Announces Proposed Appointments Of Marino Garcia And Dr. Naimish Patel To Board Of Directors
NASDAQ RESUMED AT 04:00 PM